After Nine Years of ALK Drugs, Lung Cancer Switches Gears—and a Second Mutation Saves the Day
A case report documents an ALK-rearranged lung cancer patient who acquired a druggable EGFR L858R mutation after nearly nine years ...
A case report documents an ALK-rearranged lung cancer patient who acquired a druggable EGFR L858R mutation after nearly nine years ...
A rare case report describes a patient whose bilateral bloody pleural effusions turned out to be a neutrophil-driven parapneumonic effusion ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine